Evidence map›Paper›PMID 29098010›Full record

ReviewStem cells international2017

Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?

Jan Horák, Lukáš Nalos, Vendula Martínková, Jan Beneš, Milan Štengl, Martin Matějovič

Abstract readReview
In one paragraph

Review in Stem cells international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Isolation, culture, and characterization of chicken lung-derived mesenchymal stem cells.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2018
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jan Horák1st Medical Department, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.ORCID 0000-0002-0580-9509
Lukáš NalosExperimental Intensive Care Unit, Biomedical Centre, Faculty of Medicine in Plzen, Charles University, Alej Svobody 1655/76, Plzen, Czech Republic.
Vendula MartínkováExperimental Intensive Care Unit, Biomedical Centre, Faculty of Medicine in Plzen, Charles University, Alej Svobody 1655/76, Plzen, Czech Republic.
Jan BenešExperimental Intensive Care Unit, Biomedical Centre, Faculty of Medicine in Plzen, Charles University, Alej Svobody 1655/76, Plzen, Czech Republic.
Milan ŠtenglExperimental Intensive Care Unit, Biomedical Centre, Faculty of Medicine in Plzen, Charles University, Alej Svobody 1655/76, Plzen, Czech Republic.ORCID 0000-0002-1135-0159
Martin Matějovič1st Medical Department, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.ORCID 0000-0001-9814-5256

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis, newly defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection, is the most common cause of death in ICUs and one of the principal causes of death worldwide. Although substantial progress has been made in the understanding of fundamental mechanisms of sepsis, translation of these advances into clinically effective therapies has been disappointing. Given the extreme complexity of sepsis pathogenesis, the paradigm "one disease, one drug" is obviously flawed and combinations of multiple targets that involve early immunomodulation and cellular protection are needed. In this context, the immune-reprogramming properties of cell-based therapy using mesenchymal stem cells (MSC) represent an emerging therapeutic strategy in sepsis and associated organ dysfunction. This article provides an update of the current knowledge regarding MSC in preclinical models of sepsis and sepsis-induced acute kidney injury. Recommendations for further translational research in this field are discussed.

Identifiers

PMID29098010
PMCPMC5618761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.